CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population
| Autor: | Joel S. Owen, Eleni Aklillu, Jasper Ogwal-Okeng, Ronald K Bisaso, Lars L. Gustafsson, Jackson K. Mukonzo |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Cyclopropanes Male 0301 basic medicine medicine.medical_specialty Efavirenz Genotype Anti-HIV Agents 030106 microbiology Population Antitubercular Agents HIV Infections Pharmacology 030226 pharmacology & pharmacy 03 medical and health sciences chemistry.chemical_compound Zidovudine 0302 clinical medicine Pharmacokinetics Internal medicine Genetics Humans Tuberculosis Medicine Dosing education Africa South of the Sahara education.field_of_study Coinfection business.industry Lamivudine Viral Load Benzoxazines Cytochrome P-450 CYP2B6 chemistry Alkynes HIV-1 Reverse Transcriptase Inhibitors Molecular Medicine Female Rifampin business Viral load Rifampicin medicine.drug |
| Zdroj: | Pharmacogenomics. 17:603-613 |
| ISSN: | 1744-8042 1462-2416 |
| DOI: | 10.2217/pgs.16.7 |
| Popis: | Aim: To assess genotype effect on efavirenz (EFV) pharmacokinetics, treatment outcomes and provide genotype-based EFV doses recommendations during for tuberculosis (TB)-HIV-1 cotreatment. Materials & methods: EFV concentrations from 158 HIV-TB co-infected patients treated with EFV/lamivudine/zidovidine and rifampicin were analyzed. Genotype and CD4 and viral load data were analyzed using a population PK model. Results: Simulated AUCs for 600 mg EFV dose were 1.2- and 2.4-times greater than the product label for Ugandans in general and CYP2B6*6/*6 genotypes respectively. EFV daily doses of 450 and 250 mg for Ugandans and CYP2B6*6/*6 genotypes, respectively, yielded simulated exposures comparable to the product label. Conclusions: Around 450 and 250 mg daily doses might meet EFV dosing needs of HIV-TB infected Ugandans in general and CYP2B6*6/*6 genotypes, respectively. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|